Major Depressive Disorder
Conditions
Keywords
Sodium lactate, Depression, Antidepressant, Lactate
Brief summary
The goal of this clinical trial is to test the efficacy of lactate (a natural substance) in combination with standard antidepressant treatment, in patients hospitalized for a major depressive episode. The main question\[s\] it aims to answer are: * does lactate diminishes depression severity when administered in combination with antidepressant ? * is it feasible to test lactate treatment in a large-scale clinical trial ? Participants will receive lactate intravenously daily (20 min infusion) for 5 days during hospitalisation (together with the standard antidepressant treatment). Researchers will compare with a group receiving a placebo instead of lactate to see if lactate has antidepressant effects.
Detailed description
In case of major depressive disorder (MDD), antidepressant medications are prescribed as standard treatment. The commonly used antidepressants have a delayed onset of therapeutic actions, many side effects and limited efficacy. In this regard, about 30-50% of MDD patients are unresponsive to any currently approved pharmacological treatment, emphasizing the need for novel types of drugs to treat major depression. Several animal studies have shown that lactate, a substance naturally present in the body, has antidepressant effects. The aim of this single-center study is to evaluate the feasibility of conducting a future large-scale clinical trial testing the efficacy of sodium lactate as an adjunctive treatment to a standardly prescribed antidepressant. The study is recruiting patients hospitalized for a major depressive episode. Participants are assigned randomly to the sodium lactate group or the placebo group. The study treatment will be administered intravenously daily (2mmol/kg) for 5 days during hospitalization, in addition to standard antidepressant treatment. Patients will be followed during hospitalization and then on an outpatient basis at 6 and 12 weeks. The therapeutic effect of sodium lactate will be assessed with the MADRS score (depression severity scale) at 1, 2, 3, 6 and 12 weeks. Recruitment, adherence, retention, data completion and blinding maintenance rates will also be assessed to evaluate the feasibility. The effect on anxiety, perceived stress, insomnia, short-term depression remission rate, blood lactate level and length of hospitalization will also be evaluated.
Interventions
DRUGSodium lactate
2 mmol/kg, intravenous, daily for 5 consecutive days
DRUGPlacebo
intravenous, daily for 5 consecutive days
Sponsors
Fondation de Préfargier
Centre Hospitalier Universitaire Vaudois
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Study consent signed * 18 ≤ age ≤ 65 years old * Fluent in french * Recently (no more than 1 week) hospitalized for a primary diagnosis of MDD * Current major depressive episode as defined by DSM-5 * Current MADRS score ≥18 * Total number of MDD acute episodes ≤ 3 * Total number of psychiatric medications ≤ 3 at admission * Total number of any medication ≤ 4 at admission * No signs or evidence indicating difficult intravenous access * Willing to hold a peripheral blood catheter for 5 days
Exclusion criteria
* Bipolar depression * History of panic attacks * Severe substance use disorders according to DSM-5-TR criteria * Conditions predisposing to hypernatremia such as: * adrenocortical insufficiency, * diabetes type 1 and insulin-dependent type 2 * extensive tissue injury * Known severe renal insufficiency * Known hepatic insufficiency (impaired lactate metabolism) * Known history of heart failure * Known history of Chronnic Obstructive Pulmonary Disease or respiratory failure * Known hypersentitivity to lactate * Hypernatremia with Na+ \> 150 mmol/L (confirmed on 2 blood withdrawals) * Blood osmolality \> 320 mmol/kg H2O * Hyperlactatemia \> 2 mmol/l * Pregnant or lactating * Forbiden medications : Lithium * Participation to other clinical trials * Any medical conditions that could jeopardize patient's health in case of study participation according to the investigator * Inability to give informed consent (without capacity for discernment) as evaluated by the psychiatrist investigator or by by a delegated physician.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Feasibility as assessed by the blinding maintenance rate | 12 weeks | % of patients with sustained blinding at week 1, 2, 3, 6 and 12 |
| Feasibility as assessed by the data completion rate of the therapeutic effect measures | 12 weeks | % of patients with completed Montgomery Asberg Depression Rating Scale (MADRS) questionnaire at 1, 2, 3, 6 and 12 weeks among randomized patients |
| Feasibility as assessed by the recruitment rate | 12 weeks | % of patients eligible among the informed patients |
| Feasibility as assessed by the adherence rate | 12 weeks | % of patients completing the study intervention period among randomized patients |
| Feasibility as assessed by the retention rate | 12 weeks | % of drop-outs among randomized patients at 3 weeks, 6 weeks and 12 weeks |
| Feasibility as assessed by estimates of the therapeutic effect size on Montgomery Asberg Depression Rating Scale (MADRS) score | 12 weeks | Estimate of mean difference on the change in MADRS score from baseline to week 1, 2, 3, 6 and 12 between patients randomized in lactate arm and in placebo arm, as well as their associated standard deviation. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Hospitalization duration | 12 weeks | Number of days of hospitalization |
| Perceived stress | 12 weeks | Perceived Stress Scale (PSS score) ; minimum and maximum values : 0 - 40 ; Lower scores mean a better outcome |
| Insomnia | 12 weeks | Insomnia Severity Index (ISI score) ; minimum and maximum values : 0 - 28 ; Lower scores mean a better outcome |
| Anxiety | 12 weeks | Generalized Anxiety Disorder - 7 items (GAD-7 score) ; minimum and maximum values : 0 - 21 ; Lower scores mean a better outcome |
| Short term depression remission rate | 12 weeks | Montgomery Asberg Depression Rating Scale (MADRS score \< 7) ; minimum and maximum values : 0 - 60 ; Lower scores mean a better outcome |
Contacts
Primary ContactSylfa Fassassi,, MD
Outcome results
None listed